

## Erratum to: Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy

R. Lindsay · N. B. Watts · J. L. Lange · P. D. Delmas ·  
S. L. Silverman

Published online: 29 May 2013

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

**Erratum to: Osteoporos Int**  
**DOI 10.1007/s00198-013-2332-7**

The legends for Figs. 2 and 3 appeared in the correct places but were accompanied by the wrong illustrations: Fig. 2 legend by Fig. 3 illustrations, and Fig. 3 legend by Fig. 2 illustrations. The two figures are reproduced here in their correct form.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00198-013-2332-7>.

---

R. Lindsay (✉)  
Helen Hayes Hospital, 51-55 Route 9W,  
West Haverstraw, NY 10993, USA  
e-mail: [lindsayr@helenhayeshosp.org](mailto:lindsayr@helenhayeshosp.org)


N. B. Watts  
Mercy Health Osteoporosis and Bone Health Services, Cincinnati,  
OH, USA

J. L. Lange  
Procter & Gamble, Mason, OH, USA

P. D. Delmas  
INSERM Unit 403, Université Claude Bernard Lyon 1, Lyon,  
France


S. L. Silverman  
Cedars-Sinai Medical Center and University of California, Los  
Angeles, CA, USA

**Fig. 2** Hip fracture rate. 95 % confidence intervals around point estimate. Note the early separation of the two cohorts with a lower fracture rate for risedronate than for alendronate during the early phase (6–12 months) of treatment



	Patients at risk (fracture events) by cohort at 6 month intervals				
Referent	5,390 (0)	5,371 (19)	5,353 (37)	4,428 (55)	3,621 (88)
Risedronate	12,215 (0)	8,420 (19)	5,275 (34)	3,572 (48)	2,680 (56)
Alendronate	21,615 (0)	15,239 (55)	9,745 (95)	6,877 (105)	5,144 (115)

**Fig. 3** Nonvertebral fracture rate. 95 % confidence intervals around point estimate. Note the early separation of the two cohorts with a lower fracture rate for risedronate than for alendronate during the early phase (6–12 months) of treatment



	Patients at risk (fracture events) by cohort at 6 month intervals				
Referent	5,390 (0)	5,307 (87)	5,227 (163)	4,275 (245)	3,466 (311)
Risedronate	12,215 (0)	8,346 (128)	5,205 (190)	3,505 (243)	2,619 (278)
Alendronate	21,615 (0)	15,086 (266)	9,585 (401)	6,731 (471)	5,002 (531)